Replimune Group Stock

Replimune Group P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Replimune Group (REPL) as of Aug 10, 2026 is -2.35. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -3.42 — a change of -31.42% (higher).

P/CF

-2.35

YoY

-31.42%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Replimune Group is 2026 -2.35 . P/CF (Price-to-Cash-Flow Ratio) of Replimune Group was 2025 -3.42 . It decreases by -31.42% higher compared to the previous year.
Access this data via the Eulerpool API

Replimune Group Stock analysis

What does Replimune Group do? Replimune Group Inc is an American biotechnology company based in Woburn, Massachusetts. The company focuses on the development of therapeutics for cancer treatments through the application of oncolytic viruses. Replimune Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Replimune Group stock

P/CF (Price-to-Cash-Flow Ratio) of Replimune Group is -2.35 in 2026.

P/CF (Price-to-Cash-Flow Ratio) of Replimune Group changed from -3.42 to -2.35, representing a -31.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Replimune Group since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Replimune Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Replimune Group

All Key Metrics — Replimune Group